Molecular Profiling in Routine Practice for Advanced Cancers
Limited clinical benefit achieved in the ProfiLER study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Japan Becomes the First Country to Approve Entrectinib
Tumour-agnostic medicine is approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours
Clinical Utility of Neoadjuvant Immune Checkpoint Inhibitors in Resectable NSCLC Remains Unknown
More research is also needed to identify optimal biomarkers
Which Neoadjuvant Treatment Strategy for High-Risk Resectable Melanoma?
NeoCombi and OpACIN-neo point to a critical assessment of patterns of relapse to two neoadjuvant treatment approaches
BLU-667 in RET-driven NSCLC and Thyroid Cancer
An update on the registration-enabling ARROW study
FDA Approves Pembrolizumab for Metastatic Small Cell Lung Cancer
Efficacy was investigated in patients who had disease progression on or after two or more prior lines of therapy and enrolled in the KEYNOTE-158 Cohort G or KEYNOTE-028 Cohort C1
Five-Year Survival Data in Advanced NSCLC Treated with Pembrolizumab
Latest data from KEYNOTE-001 study provide the longest efficacy/safety follow-up in this setting
Five-Year Outcomes with Combination Targeted Therapy in Metastatic Melanoma
Long terms outcomes in BRAF V600-mutated unresectable or metastatic melanoma
EMA Starts Review of Leuprorelin Medicines
Review of handling errors with depot formulations of leuprorelin medicines
FDA Approves Polatuzumab Vedotin-piiq for DLBCL
Approval is based on Study GO29365 that included a cohort of patients with relapsed or refractory diffuse large B-cell lymphoma after at least one prior regimen
Pembrolizumab in PD-L1-positive, HER2-negative Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
KEYNOTE-062 shows that front-line pembrolizumab may be promising alternative to chemotherapy
FDA Approves Pembrolizumab for First-line Treatment of HNSCC
FDA also expanded the intended use for the PD-L1 IHC 22C3 pharmDx kit to include use as a companion diagnostic for selecting patients with HNSCC